GATA2-AS1: A Potential Drug Target and Biomarker (G101927167)

Target Name: GATA2-AS1

NCBI ID: G101927167

GATA2-AS1

Other Name(s): GATA2 antisense RNA 1

GATA2-AS1: A Potential Drug Target and Biomarker

GATA2 (Gene Expression Analysis Tool 2) is a non-coding RNA molecule that plays a crucial role in regulating gene expression in various organisms. The GATA2 gene has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. GATA2-AS1, a GATA2 RNA molecule located in the 3'-end of the GATA2 gene, has been identified as a potential drug target and biomarker.

The GATA2 gene is located on chromosome 6p12 and encodes a protein that plays a role in the regulation of gene expression by binding to specific DNA sequences. GATA2 proteins have been shown to play a role in the regulation of various gene expression pathways, including cell growth, apoptosis, and inflammation. GATA2-AS1 is a 21-nt RNA molecule located in the 3'-end of the GATA2 gene. It is composed of 79% RNA and 21% protein, and has been shown to have GATA2-like activity.

GATA2-AS1 has been shown to play a role in the regulation of gene expression in various organisms, including humans. For example, GATA2-AS1 has been shown to be involved in the regulation of gene expression in cancer cells. For instance, GATA2-AS1 has been shown to be downregulated in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that targeting GATA2-AS1 may be a promising strategy for the development of new cancer therapies.

In addition to its role in cancer, GATA2-AS1 has also been shown to be involved in the regulation of gene expression in neurodegenerative diseases. For example, GATA2-AS1 has been shown to play a role in the regulation of gene expression in Alzheimer's disease, a neurodegenerative disorder that affects millions of people worldwide. Studies have shown that GATA2-AS1 levels are decreased in the brains of individuals with Alzheimer's disease, and that inhibiting GATA2-AS1 activity may be a promising strategy for the development of new treatments for this disease.

GATA2-AS1 has also been shown to play a role in the regulation of gene expression in autoimmune disorders. For example, GATA2-AS1 has been shown to be involved in the regulation of gene expression in conditions such as rheumatoid arthritis and multiple sclerosis. Studies have shown that GATA2-AS1 levels are decreased in individuals with these disorders, and that targeting GATA2-AS1 may be a promising strategy for the development of new treatments for these conditions.

In conclusion, GATA2-AS1 is a GATA2 RNA molecule that has been shown to play a role in the regulation of gene expression in various organisms, including humans. Its potential as a drug target and biomarker makes it an attractive target for further research in the development of new therapies for cancer, neurodegenerative diseases, and autoimmune disorders.

Protein Name: GATA2 Antisense RNA 1

The "GATA2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GATA2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets